Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.58 |
| ▸ | MTOR | P42345 | 14/20 | 0.58 |
| ▸ | PIK3R1 | P27986 | 6/20 | 0.58 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8079836 | 0.83 | PIK3CA (0.59) | PIK3CAMTORPIK3R1PIK3CDJAK2 | |
| SCHEMBL8062292 | 0.82 | PIK3CA (0.58) | PIK3CAMTORPIK3R1PIK3CDJAK2 | |
| SCHEMBL6900730 | 0.81 | MTOR (0.58) | PIK3CAMTORPIK3R1PIK3CBPIK3CG | |
| SCHEMBL30677407 | 0.79 | GAA (0.47) | PIK3CAMTORPIK3R1PIK3CDPIK3CB | |
| SCHEMBL31748485 | 0.76 | SRC (0.47) | PIK3CAMTORPIK3R1SRC | |
| SCHEMBL7953034 | 0.73 | PIK3CA (0.61) | PIK3CAMTORPIK3R1PIK3CDJAK2 | |
| SCHEMBL7953276 | 0.72 | PIK3CA (0.52) | PIK3CAMTORPIK3R1PIK3CDJAK2 | |
| SCHEMBL7955237 | 0.72 | PIK3CA (0.71) | PIK3CAMTORPIK3R1PIK3CDJAK2 | |
| SCHEMBL7954940 | 0.72 | PIK3CA (0.55) | PIK3CAMTORPIK3R1ALOX5APFEN1 | |
| SCHEMBL7955199 | 0.72 | FLT3 (0.53) | PIK3CAMTORPIK3R1PIK3CDJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105500-A1 | PYRAZINE SUBSTITUTED PURINES | S*BIO PTE LTD. (SG) | 2011-05-05 | — | — | US | disclosed |
| US-20110105500-A1 | PYRAZINE SUBSTITUTED PURINES | S*BIO PTE LTD. (SG) | 2011-05-05 | — | — | US | disclosed |
| WO-2009157880-A1 | PYRAZINE SUBSTITUTED PURINES | S*BIO PTE LTD (SG) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105500-A1 | PYRAZINE SUBSTITUTED PURINES | MTOR, PIK3CA, TYMP | PIK3CA 2/4885MTOR 1/4885PIK3R1 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.